Oculis Holding (OCS) Fundamentals 2026 — Revenue Analysis | SniperIQ
Oculis Holding (OCS) is a CH-listed Healthcare company in Biotechnology with a market capitalization of $663M, trading at
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Oculis Holding's market cap?
Oculis Holding (OCS) has a market capitalization of approximately $663M, trading at
What is Oculis Holding's P/E ratio?
Oculis Holding's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Oculis Holding?
Oculis Holding runs a net profit margin of -18861.3%, a gross margin of -2889.4%, and an operating margin of -16741.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Does Oculis Holding pay a dividend?
Oculis Holding does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Oculis Holding financially healthy?
Oculis Holding carries a debt-to-equity ratio of 0.01x and a current ratio of 5.18x, with a market beta of 0.20. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Oculis Holding a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Oculis Holding (OCS) the key facts are: market cap $663M, 52-week range 10.52-34.475. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Oculis Holding's full fundamentals live
Get Oculis Holding's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.